
-
South Korean president vows to build 'military trust' with North
-
Macron vows to punish antisemitic 'hatred' after memorial tree cut down
-
Hodgkinson happy to be back on track ahead of Tokyo worlds
-
Deadly monsoon rains lash Pakistan, killing dozens
-
Frank urges 'real' Spurs fans to back Tel after racist abuse
-
Japan's emperor expresses 'deep remorse' 80 years after WWII
-
Chelsea boss Maresca eager to sign new defender as Colwill cover
-
Liverpool target Isak controls his Newcastle future: Howe
-
New-look Liverpool kick off Premier League season after spending spree
-
Football and falls as first humanoid robot games launch in China
-
'Like hell': Indoor heat overwhelms Saudi Arabia's cooks, bakers
-
On VJ day, king pays tribute to UK veterans, warns of war's 'true cost'
-
Bayern's Bundesliga crown up for grabs after rocky summer
-
Arsenal face revamped Man Utd as new-look Liverpool open Premier League season
-
South Korea president vows to build 'military trust' with North
-
'Never again': Indigenous Bolivians sour on socialism
-
Indonesia's president touts economy, social welfare drive
-
World plastic pollution treaty talks collapse with no deal
-
Facing US tariffs, India's Modi vows self-reliance
-
Trump to meet Putin in high-stakes Alaska summit
-
Indian rescuers scour debris after 60 killed in flood
-
Ivory Coast village reburies relatives as rising sea engulfs cemetery
-
Stressed UK teens seek influencers' help for exams success
-
National Guard deploys 800 personnel for DC mission, says Pentagon
-
Japan emperor expresses 'deep remorse' 80 years after WWII
-
With waters at 32C, Mediterranean tropicalisation shifts into high gear
-
Historic Swedish church being moved as giant mine casts growing shadow
-
Malawi's restless youth challenged to vote in September polls
-
Indonesian roof tilers flex muscles to keep local industry alive
-
World's first humanoid robot games begin in China
-
Scott Barrett returns to lead All Blacks against Argentina
-
Five things to know about Nigeria's oil sector
-
New compromise but still no deal at plastic pollution talks
-
France's Cernousek seizes lead at LPGA Portland Classic
-
Putin-Trump summit: What each side wants
-
Desperate Myanmar villagers scavenge for food as hunger bites
-
Asia stocks mixed before US-Russia summit
-
Putin hails North Korean troops as 'heroic' in letter to Kim
-
Fleeing the heat, tourists explore Rome at night, underground
-
Online cockfighting thrives in Philippines despite ban and murders
-
Keeping cool with colours -- Vienna museum paints asphalt to fight heat
-
Raising the bar: Nepal's emerging cocktail culture
-
El Salvador plans 600 mass trials for suspected gang members
-
Trump's tariffs drown Brazil's fish industry
-
Hong Kong tycoon Jimmy Lai's collusion trial resumes after delay
-
Britain's Princess Anne turns 75 with typically minimal fuss
-
Japan posts modest growth despite US tariffs
-
Rugby Championship kicks off amid uncertain future
-
Israeli far-right minister backs contentious West Bank settlement plan
-
Hot putter carries MacIntyre to three-shot lead at BMW Championship

More Ebola trial vaccines arrive in Uganda
Uganda announced Thursday that it had received shipments of two more trial vaccines to test against a strain of Ebola responsible for dozens of deaths in the East African nation.
Since authorities declared an Ebola outbreak on September 20, Uganda has registered 142 confirmed cases and 56 deaths, but the spread has slowed in recent weeks, sparking hope that the epidemic could be on its way out.
The outbreak has been caused by the so-called Sudan strain of the virus, for which there is currently no vaccine.
But three candidate vaccines -- one developed by Oxford University and the Jenner Institute in Britain, another from the Sabin Vaccine Institute in the United States, and a third from the International AIDS Vaccine Initiative (IAVI) -- will be trialed in Uganda in the coming weeks.
On December 8, Uganda received its first shipment of doses from the Sabin Vaccine Institute.
"On Saturday December 17, we received two more candidate vaccines from Merck/IAVI of 2,160 doses and 2,000 doses from Oxford University/Jenner Institute manufactured by the Serum Institute of India," Health Minister Jane Ruth Aceng told a press briefing on Thursday.
They will be used in a so-called ring vaccination trial, where all contacts of confirmed Ebola patients, and contacts of contacts, are jabbed along with frontline and health workers.
Ugandan authorities said last month that new cases were falling, and the last confirmed patient with the disease was discharged from hospital on November 30.
The absence of active Ebola cases in recent days has held up the vaccine trials, according to international health experts working in Uganda.
Aceng said however that the authorities had already begun enlisting volunteers for the trials, adding that Uganda would take part in a global expert consultation meeting on Ebola on January 12.
The government last week lifted a two-month lockdown on two Ebola hotspots, removing curbs including a dusk-to-dawn curfew, a ban on personal travel and the closure of markets, bars and churches.
According to the World Health Organization (WHO), an outbreak of the disease ends when there are no new cases for 42 consecutive days -- twice the incubation period of Ebola.
Ebola spreads through bodily fluids. Common symptoms are fever, vomiting, bleeding and diarrhoea.
Outbreaks are difficult to contain, especially in urban environments.
Y.Bouchard--BTB